By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today said that it has received commitments from certain investors to purchase around $7 million worth of the firm's stock in a registered direct offering.

The Fremont, Calif.-based firm said that among those investors is its Chairman and CEO, Alnoor Shivji, who has agreed to purchase $1 million worth of securities in the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.